Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Parental longevity is associated with an increased life expectancy; results with regard to specific diseases are conflicting. There are limited data focusing on host characteristics and their effect on survival among multiple myeloma (MM) patients and individuals with monoclonal gammopathy of undetermined significance (MGUS). Therefore, our aim was to evaluate the impact of parental longevity on survival of patients with MM and MGUS. A total of 4675 patients with MM, 6812 MGUS patients and 13 398 population-based controls for MM as well as 19 110 controls for MGUS, from 1988 to 2013, were included in the study. Longevity was defined as >90 years of age. Among MM patients, parental longevity was associated with a decreased risk of death [hazard ratio (HR) = 0·92, 95% confidence interval (CI) 0·84–0·99] and the same was true for MGUS patients (HR = 0·87, 95% CI 0·78–0·96). Having one long lived parent significantly decreased the risk of death in both groups, but was not statistically significant when both parents exceeded 90 years of age. In conclusion, parental longevity decreases the risk of death for patients with MM and MGUS which may reflect the importance of the host's genetic and environmental factors in relation to survival.


  • Ingigerður S. Sverrisdóttir
  • Sigrún H. Lund
  • Ingemar Turesson
  • Magnus Björkholm
  • Lynn R. Goldin
  • Ola Landgren
  • Sigurður Y. Kristinsson
Externa organisationer
  • National University Hospital of Iceland
  • University of Iceland
  • Skåne University Hospital
  • Karolinska University Hospital
  • National Cancer Institute
  • Memorial Sloan-Kettering Cancer Center

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi


TidskriftBritish Journal of Haematology
StatusE-pub ahead of print - 2019
Peer review utfördJa
Externt publiceradJa